Abstract
A brain-penetrant BRAF inhibitor demonstrates potent activity in brain metastatic melanoma, even upon relapse following standard BRAF inhibitor therapy, supporting further investigation into its clinical utility.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have